GlassScriptPhysician profile
Andrew S Kirschner
NPI 1710927306
$2,197.56
in general payments reported to CMS, 2019-2025
24 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $345 · 2020: $190 · 2021: $484 · 2022: $313 · 2023: $267 · 2024: $263 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $866.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.23 | 2021-2025 | |
| Allergan, INC. | $338.01 | 2019-2020 | |
| Braeburn INC. | $209.31 | 2024-2025 | Brixadi |
| Kowa Pharmaceuticals America, INC. | $126.57 | 2022-2024 | Seglentis, Livalo |
| Indivior INC. | $107.98 | 2021-2025 | Sublocade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.54 | 2019-2023 | Cycloset |
| Biohaven Pharmaceutical Holding Company LTD. | $96.07 | 2022 | |
| Pear Therapeutics (US), INC. | $95.48 | 2021 | |
| Pfizer INC. | $93.58 | 2023-2024 | |
| Lilly USA, LLC | $83.94 | 2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceuticals, INC. | $75.73 | 2021 | |
| Kaleo, INC. | $61.08 | 2019 | |
| Bausch Health US, LLC | $46.71 | 2021-2022 | |
| Alkermes, INC. | $45.32 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.40 | 2025 | Caplyta |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $29.11 | 2025 | |
| Astellas Pharma US INC | $25.80 | 2025 | Veozah |
| Abbott Laboratories | $20.96 | 2024 | Proclaim |
| Genentech USA, INC. | $20.66 | 2019 | |
| Electronic Waveform Lab, INC. | $15.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.40 | 2021 | |
| Qiagen, LLC | $15.16 | 2023 | |
| Gilead Sciences, INC. | $13.93 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.91 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Kirschner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.